<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385342</url>
  </required_header>
  <id_info>
    <org_study_id>R.20.04.823</org_study_id>
    <nct_id>NCT04385342</nct_id>
  </id_info>
  <brief_title>FSH Followed by HMG vs FSH Plus HMG in IVF</brief_title>
  <official_title>Follicle Stimulating Hormone (FSH) Followed by Human Menopausal Gonadotropin (HMG) Versus FSH Plus HMG During Controlled Ovarian Stimulation for in Vitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the clinical outcomes of sequential administration of FSH
      and HP-hMG FSH alone versus concomitant administration of FSH and HP-hMG during controlled
      ovarian stimulation in IVF cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women who are planned to be subjected to IVF/ICSI through COS by long GnRHa protocol will be
      assessed for possibility of participation in our study. Eligible participants in our study
      will be those with regular menstrual cycle (21-35 days) and normal uterine anatomy (confirmed
      by transvaginal ultrasound examination and in some cases hysteronsalpingography and
      hysteroscopy).

      Women with any of the following criteria will be excluded from the study: 1) age &lt; 20 or &gt; 37
      years; 2) body mass index (BMI) &lt; 18 or &gt; 25 kg/m2; 3) low ovarian reserve (AFC &lt; 7 and/or
      AMH &lt; 1.1 ng/ml); 4) presence of polycystic ovarian syndrome (PCOS), endometrioma or
      hydrosalpinx; 5) history of chemotherapy, radiotherapy or ovarian surgery; 6) the husband
      needs testicular biopsy to obtain sperm; or 7) previous implantation failure.

      A written informed consent will be taken from each women selected to participate before
      inclusion in the study. All women participating in the study will start GnRHa on day 21 of
      the preceding cycle and when down regulation occurs each woman will be randomly allocated
      into one of the two groups; group 1 and group 2. Women in group 1 will receive 225 IU FSH
      alone from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm,
      the 150 IU HP-hMG will substitute FSH and continued to the day of triggering. Women in group
      2 will receive 150 IU FSH plus 75 IU HP-hMG from day one of ovarian stimulation and 150IU
      HP-HMG when the follicular diameters reaches 10-12 mm till day of triggering. The
      randomization will be simple and balanced (1:1) and will be carried out by a nurse through
      sealed, unlabeled, opaque envelopes containing computer-generated random numbers. The data
      assesor will be blinded to group assignment.

      In both groups, estradiol and LH will be measured on the third day of menstruation before
      start of stimulation and on day 6 of stimulation TVS will be performed. Progesterone and E2
      will be measured and on day of triggering. The primary outcome measure of this study will be
      the ongoing pregnancy rate. The secondary outcomes measures will be cancellation rate, the
      number of oocytes retrieved, the number of embryos, the number of vitrified embryos, the
      clinical pregnancy rate, the implantation rate, OHSS rate, multiple pregnancy rate, and the
      miscarriage rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks gestational age</time_frame>
    <description>Number of ongoing pregnancies (defined as pregnancies passed beyond 12 weeks gestational age) divided by the number of women randomized</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>6 weeks after embryo transfer</time_frame>
    <description>Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of women randomized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>6 weeks after embryo transfer</time_frame>
    <description>Number of gestational sacs on TVS scan at 4-6 weeks after ET divided by the number of transferred embryos</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>12 weeks gestational age</time_frame>
    <description>Number of first trimester miscarriages (before 12 weeks gestational age) divided by the number of clinical pregnancies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>FSH then HP-hMG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive 225 IU FSH alone from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm, the 150 IU HP-hMG will substitute FSH and continued to the day of triggering</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH + HP-hMG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive 150 IU FSH plus 75IU HP-hMG from day one of ovarian stimulation and when the follicular diameters reaches 10-12 mm 150 IU HP-HMG till day of triggering</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FSH</intervention_name>
    <description>Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG</description>
    <arm_group_label>FSH + HP-hMG</arm_group_label>
    <arm_group_label>FSH then HP-hMG</arm_group_label>
    <other_name>Fostimon, Gonal-F, Puragon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HP-hMG</intervention_name>
    <description>Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG</description>
    <arm_group_label>FSH + HP-hMG</arm_group_label>
    <arm_group_label>FSH then HP-hMG</arm_group_label>
    <other_name>Meriofert, Menopure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who are planned to be subjected to IVF/ICSI through COS by long GnRHa protocol.

          -  Women with regular menstrual cycle (21-35 days) and normal uterine anatomy (confirmed
             by transvaginal ultrasound examination and in some cases hysteronsalpingography and
             hysteroscopy).

        Exclusion Criteria:

          -  Age &lt; 20 or &gt; 37 years.

          -  Body mass index (BMI) &lt; 18 or &gt; 30 kg/m2.

          -  Low ovarian reserve (AFC &lt; 7 and/or AMH &lt; 1.1 ng/ml).

          -  Presence of polycystic ovarian syndrome (PCOS).

          -  Endometrioma or hydrosalpinx.

          -  History of chemotherapy, radiotherapy or ovarian surgery.

          -  The husband needs testicular biopsy to obtain sperm.

          -  Previous implantation failure.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Gibreel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed S Abdelhafez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasan El Maghraby, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hamed Yossef, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Gibreel, MD</last_name>
    <phone>01221191133</phone>
    <email>ahmedfathgi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fertility Care Unit (FCU) in Mansoura University Hospital</name>
      <address>
        <city>Mansourah</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hamed Yossef, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasan El Maghraby, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>RAHEM Fertility Centre</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eman Elgindy, PhD</last_name>
      <email>eman_elgindy2013@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian stimulation</keyword>
  <keyword>subfertility</keyword>
  <keyword>FSH</keyword>
  <keyword>HMG</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

